Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound

Network-Directed Anti-Amyloid Immunotherapy connectomics market 41% proposed
Composite
35%
Novelty
80%
Feasibility
25%
Impact
40%
Mechanistic
45%
Druggability
35%
Safety
30%
Confidence
35%

Mechanistic description

Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound

Evidence for (5)

  • Hub regions show preferential amyloid deposition due to high activity-dependent amyloid production

    PMID:19219025

  • tFUS-mediated BBB opening enables targeted delivery to specific brain regions

    PMID:29422609

  • Network-level degeneration in AD follows connectivity patterns - hubs are vulnerable

    PMID:20644199

  • Exablate Neuro FDA-approved for essential tremor/PD - regulatory pathway exists

    PMID:31046252

  • Amyloid clearance (60-80% PET reduction) achievable with antibodies

    PMID:31881167

Evidence against (5)

  • tFUS spatial precision limited to 2-5mm - sub-centimeter hub targeting unachievable

    PMID:35101508

  • Even robust amyloid clearance (lecanemab/donanemab) produces only 27-35% clinical slowing

    PMID:31881167

  • Amyloid clearance fails to restore functional connectivity to normal levels

    PMID:34019835

  • FcRn-mediated IgG recycling provides substantial brain penetration without tFUS

    PMID:31881167

  • 40-60% enhancement prediction lacks empirical basis - unsubstantiated numerical claim

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.